ArticleInternational journal of cardiology. Heart & vasculature2021
Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial.
Article in International journal of cardiology. Heart & vasculature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Effects of atorvastatin on inflammatory markers, lipid profile, liver enzymes, and pulmonary function in patients with lung diseases: a systematic review and meta-analysis of randomized controlled trials.European journal of medical research · 2026Pooled it
- Adjunctive therapy with lipid-lowering agents in COVID-19: a systematic review and meta-analysis of randomized controlled trials.Lipids in health and disease · 2023Pooled it
- Effects of statin therapy in hospitalized adult COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.Einstein (Sao Paulo, Brazil) · 2023Pooled it
- Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials.British journal of clinical pharmacology · 2022Pooled it
- The Effectiveness of Mini-Pulse Methylprednisolone in the Treatment of Patients With COVID-19 in the Intensive Care Unit.Immunity, inflammation and disease · 2024Trial
- Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial.Respiratory research · 2024Trial
- Survival of the hospitalized patients with COVID-19 receiving atorvastatin: A randomized clinical trial.Journal of medical virology · 2022Trial
- Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial.BMJ (Clinical research ed.) · 2022Trial
- Computational proteomics to enhance personalized treatment of COVID-19 and Long COVID.Clinical proteomics · 2026Review
- Different SARS-CoV-2 Subvariants and Coagulation Markers Trend: A Retrospective Multicentric Study From Iranian Network for Research in Viral Diseases (INRVD).Health science reports · 2026Article
- Observational
- A Dual Pharmacological Strategy against COVID-19: The Therapeutic Potential of Metformin and Atorvastatin.Microorganisms · 2024Review
- Statin Use in Relation to COVID-19 and Other Respiratory Infections: Muscle and Other Considerations.Journal of clinical medicine · 2023Review
- Treating COVID-19: Targeting the Host Response, Not the Virus.Life (Basel, Switzerland) · 2023Review
- The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study.Archivum immunologiae et therapiae experimentalis · 2023Article
- Statins: Beneficial Effects in Treatment of COVID-19.Advances in experimental medicine and biology · 2023Article
- Phenotypical and Functional Alteration of γδ T Lymphocytes in COVID-19 Patients: Reversal by Statins.Cells · 2022Article
- Effects of statins on clinical outcomes in hospitalized patients with COVID-19.European journal of internal medicine · 2022Article
- Senility and COVID-19 as two possible risk factors for loss of consciousness: A rare case report.Annals of medicine and surgery (2012) · 2022Article
- Attitudes and Knowledge of Infertile Iranian Couples Among Treatment With Assisted Reproductive Technologies During COVID-19 Pandemics.Journal of family & reproductive health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEfficacious therapies are urgently required to tackle the coronavirus disease 2019 (COVID-19). This trial aims to evaluate the effects of atorvastatin in comparison with standard care for adults hospitalized with COVID-19.
methodsWe conducted a randomized controlled clinical trial on adults hospitalized with COVID-19. Patients were randomized into a treatment group receiving atorvastatin + lopinavir/ritonavir or a control group receiving lopinavir/ritonavir alone. The primary outcome of the trial was the duration of hospitalization. The secondary outcomes were the need for interferon or immunoglobulin, receipt of invasive mechanical ventilation, and O2 saturation (O2sat), and level of C-reactive protein (CRP) which were assessed at the onset of admission and on the 6th day of treatment.
resultsForty patients were allocated and enrolled in the study with a 1 to 1 ratio in atorvastatin + lopinavir/ritonavir and lopinavir/ritonavir groups. Clinical and demographic characteristics were similar between the two groups. CRP level was significantly decreased in the lopinavir/ritonavir + atorvastatin group (P < 0.0001, Cohen's d = 0.865) so that there was a significant difference in CRP level on the 6th day between the two groups (P = 0.01). Nevertheless, there was no significant difference in O2sat on day 6. Although the duration of hospitalization in the lopinavir/ritonavir + atorvastatin group was significantly reduced compared to the control group (P = 0.012), there was no significant difference in the invasive mechanical ventilation reception and the need for interferon and immunoglobulin.
conclusionAtorvastatin + lopinavir/ritonavir may be more effective than lopinavir/ritonavir in treating COVID-19 adult hospitalized patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.